Search company, investor...

Founded Year



Other Investors | Alive

About Bikam

Bikam supplies all kinds of scientific and professional literature. It offers a subscription order for government and non-government organizations, commercial representatives, higher educational institutions, and more. It was founded in 1996 and is based in Sofia, Bulgaria.

Headquarters Location

Oborishte Street 52



00359 2 843 52 80



Latest Bikam News

General : Five-year-old boy drowns in Sungai Jerong Bikam

Jan 3, 2021

TAPAH, Dec 3  -- A five-year-old boy drowned when he lost his balance and was swept away by currents while playing in Sungai Jerong Bikam, Sungkai, 24.6 kilometre from here, today.

Bikam Frequently Asked Questions (FAQ)

  • When was Bikam founded?

    Bikam was founded in 1996.

  • Where is Bikam's headquarters?

    Bikam's headquarters is located at Oborishte Street 52, Sofia.

  • What is Bikam's latest funding round?

    Bikam's latest funding round is Other Investors.

  • Who are the investors of Bikam?

    Investors of Bikam include CHL Medical Partners and F-Prime Capital.

  • Who are Bikam's competitors?

    Competitors of Bikam include Applied Genetic Technologies, DiscoveryBioMed, Lycera, Echelon Biosciences, IRX Therapeutics and 7 more.


Compare Bikam to Competitors

Active Pass Pharmaceuticals

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

Genelabs Technologies

is discovering compounds that selectively inhibit replication of the hepatitis C virus, and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also developing a late-stage product for lupus. They aim to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate.

Echelon Biosciences Logo
Echelon Biosciences

Echelon Biosciences is a company that focuses on biochemical reagents, assays, and peptides within the academic research and pharmaceutical development sectors. The company offers a range of products and services including antibodies, proteins, biochemical reagents, and custom synthesis services, all designed to support scientific research and development. Echelon Biosciences primarily serves the academic research and pharmaceutical development industries. It is based in Salt Lake City, Utah.

Terpenoid Therapeutics

Terpenoid Therapeutics is a drug discovery and development company focused on treatments for cancer. The company are developing a portfolio of small molecule- based compounds primarily for treatment of prostate, brease, brain, lung and colon cancers.


VivoPath is a preclinical screening company, offering the company's clients discovery and development services for in vivo testing. VivoPath aims to provide integrated in vivo studies led by established experts in drug development. Efficacy is established for animal models in the areas of metabolic disease, inflammation, neurodegenerative disease, and infectious diseases. Formulation screening is carried out to select the most appropriate delivery system for administration. Pharmacokinetic evaluation is carried out to assess exposure and bioavailability. Tolerability is assessed with evaluations of clinical signs, clinical chemistry and hematology. The resulting program aims to deliver the client an in vivo therapeutic index (TI) report on which to assess candidates for subsequent development. VivoPath can also help clients at any individual step in this preclinical screening process. VivoPath's commitment is to provide scientific expertise in in vivo drug discovery in order to increase productivity from research into drug development.


GNI's "gene network" technology is based on a combination of wet lab work and lots of computing power to figure out how the 30,000-plus protein-making genes in the human genome interact. Its primary product is a drug discovery engine to quickly identify genes for drug development, as well as figure out which genes are affected by a given drug.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.